{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:55:23Z","timestamp":1788432923661,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To date, it is still unknown whether orodispersible tablet (ODT) ticagrelor might represent a suitable way to reach a proper antiaggregation in acute coronary syndrome (ACS) patients receiving morphine. Aim of the present study was to evaluate platelet inhibition with 180\u00a0mg ticagrelor loading dose (LD) administered as ODT compared with standard coated tablet ticagrelor formulation in ACS patients undergoing percutaneous coronary intervention (PCI) according to morphine use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and Results<\/jats:title>\n                  <jats:p>One-hundred and 30 patients presenting with STEMI or very high-risk NSTE-ACS were randomly assigned to receive ODT or standard ticagrelor LD. Potential morphine-ticagrelor interaction was assessed by stratified randomization according to morphine use. Platelet reactivity was evaluated by Platelet Reactivity Units (PRU) VerifyNow\u2122 1, 2, 4, and 6 h after ticagrelor LD. The primary endpoint was residual platelet reactivity 1 h after LD across the two ticagrelor formulation and according to morphine use. Safety endpoints were major bleedings and other in-hospital ticagrelor administration-related adverse events. One hour after LD, PRU median value was higher in morphine-treated patients (N\u00a0=\u00a032) as compared with patients not receiving morphine (N\u00a0=\u00a098; PRU\u00a0=\u00a0187 [70\u2013217]) vs. 73 [7\u2013187]; P\u00a0=\u00a00.012). In patients with morphine, 1-h PRU values were similar between study groups (192 [114\u2013236] vs. 173 [16\u2013215] in ODT and standard tablet ticagrelor, respectively). Similarly, in patients without morphine, 1-h PRU values were not significantly different between study groups (69 [8\u2013152] vs. 110 [6\u2014193] in ODT and standard tablet ticagrelor, respectively). Platelet reactivity appeared similar in the 2 study arms at 2, 4, and 6 h after LD. No significant difference was observed among patients with or without morphine regarding in-hospital adverse events or drug side-effects, even if a reinfarction due to acute stent thrombosis was observed in a patient treated with morphine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There was no difference between ODT and standard ticagrelor tablets in terms of post-LD residual platelet reactivity, percentage of platelet inhibition or safety regardless to morphine use.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvad061","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T12:45:09Z","timestamp":1692189909000},"page":"692-700","source":"Crossref","is-referenced-by-count":9,"title":["Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9718-9107","authenticated-orcid":false,"given":"Guido","family":"Parodi","sequence":"first","affiliation":[{"name":"Cardiology Unit, Department of Medicine, Lavagna Hospital , Via Don Bobbio 25, 16033, Lavagna (Ge) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3830-7828","authenticated-orcid":false,"given":"Filippo","family":"Dossi","sequence":"additional","affiliation":[{"name":"Interventional Cardiology Unit - Department of Emergency; ASST-Lariana, Sant'Anna Hospital , Via Ravona 20, 22042, San Fermo della Battaglia (CO) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-638X","authenticated-orcid":false,"given":"Mario","family":"Raccis","sequence":"additional","affiliation":[{"name":"Clinical and Interventional Cardiology, Sassari University Hospital , Via Enrico de Nicola 39, 07100, Sassari (SS) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Talanas","sequence":"additional","affiliation":[{"name":"Clinical and Interventional Cardiology, Sassari University Hospital , Via Enrico de Nicola 39, 07100, Sassari (SS) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Mura","sequence":"additional","affiliation":[{"name":"Cardiology Department, San Francesco Hospital , Via S. Mannironi, 08100, Nuoro (NU) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Siciliano","sequence":"additional","affiliation":[{"name":"Clinical and Interventional Cardiology, Sassari University Hospital , Via Enrico de Nicola 39, 07100, Sassari (SS) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Guarino","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Umberto I Hospital , Contrada Ferrante, 94100, Enna (EN) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Marini","sequence":"additional","affiliation":[{"name":"Cardiology Department , Giovanni Paolo II, Via Bazzoni-Sircana 2\/2A, 07026, Olbia (SS) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7354-9905","authenticated-orcid":false,"given":"Paolo","family":"Franca","sequence":"additional","affiliation":[{"name":"Clinical and Interventional Cardiology, Sassari University Hospital , Via Enrico de Nicola 39, 07100, Sassari (SS) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-8491","authenticated-orcid":false,"given":"Pier Sergio","family":"Saba","sequence":"additional","affiliation":[{"name":"Clinical and Interventional Cardiology, Sassari University Hospital , Via Enrico de Nicola 39, 07100, Sassari (SS) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe D","family":"Sanna","sequence":"additional","affiliation":[{"name":"Clinical and Interventional Cardiology, Sassari University Hospital , Via Enrico de Nicola 39, 07100, Sassari (SS) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E","family":"Canonico","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II , Via Pansini 5, 80131, Napoli (NA) , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"2023121405273268600_bib1","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2023121405273268600_bib2","first-page":"e362","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume-title":"Circulation","author":"O'Gara","year":"2013"},{"key":"2023121405273268600_bib3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s40261-017-0554-8","article-title":"Pharmacokinetic profiles of ticagrelor orodispersible tablets in healthy Western and Japanese subjects","volume":"37","author":"Teng","year":"2017","journal-title":"Clin Drug Investig"},{"key":"2023121405273268600_bib4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jacc.2021.05.015","article-title":"Orodispersible ticagrelor in acute coronary syndromes: the TASTER study","volume":"78","author":"Parodi","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023121405273268600_bib5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ijcard.2016.06.204","article-title":"Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI","volume":"221","author":"Bellandi","year":"2016","journal-title":"Int J Cardiol"},{"key":"2023121405273268600_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1517\/17425247.2016.1142971","article-title":"Challenges in in oral drug delivery in patients with esophageal dysphagia","volume":"13","author":"Kappelle","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"2023121405273268600_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2015.04.012","article-title":"Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap","volume":"170","author":"Alexopoulos","year":"2015","journal-title":"Am Heart J"},{"key":"2023121405273268600_bib8","doi-asserted-by":"crossref","first-page":"e001593","DOI":"10.1161\/CIRCINTERVENTIONS.114.001593","article-title":"Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention","volume":"8","author":"Parodi","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"2023121405273268600_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2016","journal-title":"Eur Heart J"},{"key":"2023121405273268600_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ehjcvp\/pvaa095","article-title":"Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: opioids aNd crushed ticagrelor In myocardial infarction evaluation (ON-TIME 3) trial","volume":"8","author":"Tavenier","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023121405273268600_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1160\/TH15-12-0944","article-title":"P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study","volume":"116","author":"Silvain","year":"2016","journal-title":"Thromb Haemost"},{"key":"2023121405273268600_bib12","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2023121405273268600_bib13","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jacc.2010.03.103","article-title":"Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T\/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and\/or resistance to clopidogrel) trial substudy","volume":"56","author":"Campo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2023121405273268600_bib14","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2023121405273268600_bib15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.jacc.2020.09.586","article-title":"Ticagrelor or prasugrel for platelet inhibition in acute coronary syndrome patients: the ISAR-REACT 5 trial","volume":"76","author":"Mayer","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023121405273268600_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1160\/TH16-02-0102","article-title":"Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction","volume":"116","author":"Thomas","year":"2016","journal-title":"Thromb Haemost"},{"key":"2023121405273268600_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40262-015-0320-0","article-title":"Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic\/pharmacodynamic study","volume":"55","author":"Alexopoulos","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2023121405273268600_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","article-title":"Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study","volume":"65","author":"Parodi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023121405273268600_bib19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2023121405273268600_bib20","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1001\/jamacardio.2017.3868","article-title":"Effect of chewing vs swallowing ticagrelor on platelet inhibition in patients with ST-segment elevation myocardial infarction: a randomized clinical trial","volume":"2","author":"Asher","year":"2017","journal-title":"JAMA Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvad061\/51331363\/pvad061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/8\/692\/54021871\/pvad061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/8\/692\/54021871\/pvad061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T05:28:04Z","timestamp":1702531684000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/9\/8\/692\/7244691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,17]]},"published-print":{"date-parts":[[2023,12,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvad061","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,8,17]]}}}